Evoke Pharma, Inc.
EVOK · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $10,249 | $5,181 | $2,509 | $1,618 |
| % Growth | 97.8% | 106.5% | 55% | – |
| Cost of Goods Sold | $357 | $202 | $370 | $328 |
| Gross Profit | $9,893 | $4,979 | $2,138 | $1,290 |
| % Margin | 96.5% | 96.1% | 85.2% | 79.7% |
| R&D Expenses | $16 | $182 | $301 | $590 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $15,081 | $12,228 | $9,624 | $8,851 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $15,097 | $12,410 | $9,924 | $9,442 |
| Operating Income | -$5,204 | -$7,431 | -$7,786 | -$8,152 |
| % Margin | -50.8% | -143.4% | -310.4% | -503.8% |
| Other Income/Exp. Net | -$148 | -$361 | -$438 | -$386 |
| Pre-Tax Income | -$5,352 | -$7,792 | -$8,224 | -$8,538 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5,352 | -$7,792 | -$8,224 | -$8,538 |
| % Margin | -52.2% | -150.4% | -327.8% | -527.7% |
| EPS | -2.81 | -27.97 | -31.16 | -40.4 |
| % Growth | 90% | 10.2% | 22.9% | – |
| EPS Diluted | -2.81 | -27.97 | -31.16 | -40.4 |
| Weighted Avg Shares Out | 1,905 | 279 | 262 | 224 |
| Weighted Avg Shares Out Dil | 1,905 | 279 | 262 | 224 |
| Supplemental Information | – | – | – | – |
| Interest Income | $353 | $139 | $62 | $9 |
| Interest Expense | $501 | $500 | $500 | $500 |
| Depreciation & Amortization | $5,204 | $139 | $0 | $0 |
| EBITDA | $353 | -$7,154 | -$7,724 | -$8,038 |
| % Margin | 3.4% | -138.1% | -307.9% | -496.8% |